Protective Effect of Modified Suanmei-Tang on Metabolic-Associated Fatty Liver Disease: An Integrated Strategy of Network Pharmacology, Metabolomics, and Transcriptomics
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s478072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Chao Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Traditional Chinese Medicine Department, Qitai Hospital of the Sixth Division, Xinjiang, 831899, People's Republic of China. Hauptthemen laut MEDLINE: Network Pharmacology, Drugs, Chinese Herbal, Metabolomics, Mice, Inbred C57BL. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Modified Suanmei-Tang (MST) comprises four plants common to both traditional Chinese medicine and culinary applications, and it can potentially alleviate metabolic-associated fatty liver disease (MAFLD) triggered by a high-fat diet (HFD).
Purpose
This research aims to investigate the impact and underlying mechanisms of MST in ameliorating MAFLD caused by an HFD.
Methods
UHPLC-Q-Orbitrap-MS/MS was used to determine the constituents of MST and to evaluate its effects on MAFLD mouse models. Transcriptomics, network pharmacology, and bioinformatics analysis (including Kyoto Encyclopedia of Genes and Genomes and Gene Set Enrichment Analysis) were utilized to further clarify the mechanisms by which MST acts on MAFLD. The experimental methods included ELISA, real time quantitative PCR (RT-qPCR), Western blot, immunohistochemistry, molecular docking, and metabolomics. Transcriptomics was integrated with metabolomics to find correlations between differentially expressed genes and metabolites, and crucial genes were validated through RT-qPCR.
Results
A total of 23 components of MST were identified. The formulation was found to alleviate metabolic disorders, obesity, insulin resistance, inflammation, and oxidative stress in mice with MAFLD. The findings indicate that MST promoted autophagy by suppressing phosphorylation in the PI3K/AKT/mTOR pathway and enhancing lipid management in the livers of MAFLD mice.
Conclusion
MST could effectively improve lipid metabolism disorders and liver lipid deposition in MAFLD mice, and its mechanism might be related to regulating the PI3K/AKT/mTOR pathway to improve autophagy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Traditional Chinese Medicine Department, Qitai Hospital of the Sixth Division, Xinjiang, 831899, People's Republic of China.
- College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, People's Republic of China.
- Department of Ultrasound, Chengdu First People's Hospital, Chengdu, 610095, People's Republic of China.
- Institute of Traditional Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences, Chengdu, 610014, People's Republic of China.
Zitieren
APA
Wang, C., Zhao, M., Yue, Y., Hu, C., Zhou, C., Zhang, Z., He, Y., Luo, Y., Shen, T., Dang, S., Yang, Y., & Zhang, Y. (2024). Protective Effect of Modified Suanmei-Tang on Metabolic-Associated Fatty Liver Disease: An Integrated Strategy of Network Pharmacology, Metabolomics, and Transcriptomics. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s478072
Vancouver
Wang C, Zhao M, Yue Y, Hu C, Zhou C, Zhang Z, et al. Protective Effect of Modified Suanmei-Tang on Metabolic-Associated Fatty Liver Disease: An Integrated Strategy of Network Pharmacology, Metabolomics, and Transcriptomics. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s478072
BibTeX
@article{Wang2024,
author = {Wang, Chao and Zhao, Mei and Yue, Yuanyuan and Hu, Chao and Zhou, Chunqiu and Zhang, Zhongyi and He, Yunliang and Luo, Yaqi and Shen, Tao and Dang, Sijie and Yang, Yang and Zhang, Yong},
title = {Protective Effect of Modified Suanmei-Tang on Metabolic-Associated Fatty Liver Disease: An Integrated Strategy of Network Pharmacology, Metabolomics, and Transcriptomics},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s478072}
}
EUVIMED